NO329483B1 - Fremgangsmate for okning av utbyttet av et interferon alfa-preparat. - Google Patents
Fremgangsmate for okning av utbyttet av et interferon alfa-preparat. Download PDFInfo
- Publication number
- NO329483B1 NO329483B1 NO20012327A NO20012327A NO329483B1 NO 329483 B1 NO329483 B1 NO 329483B1 NO 20012327 A NO20012327 A NO 20012327A NO 20012327 A NO20012327 A NO 20012327A NO 329483 B1 NO329483 B1 NO 329483B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- pyruvate
- isoform
- supplement
- interferon alpha
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 40
- 108010047761 Interferon-alpha Proteins 0.000 title claims description 20
- 102000006992 Interferon-alpha Human genes 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000001965 increasing effect Effects 0.000 title claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 claims description 75
- 108010029485 Protein Isoforms Proteins 0.000 claims description 75
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 56
- 239000013589 supplement Substances 0.000 claims description 39
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 229950000038 interferon alfa Drugs 0.000 claims description 3
- 229960003507 interferon alfa-2b Drugs 0.000 claims description 3
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 description 77
- 108090000623 proteins and genes Proteins 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 76
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000007254 oxidation reaction Methods 0.000 description 20
- 230000007062 hydrolysis Effects 0.000 description 17
- 238000006460 hydrolysis reaction Methods 0.000 description 17
- 230000003647 oxidation Effects 0.000 description 17
- 229940116540 protein supplement Drugs 0.000 description 14
- 235000005974 protein supplement Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010055511 interferon alfa-2c Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19054298A | 1998-11-12 | 1998-11-12 | |
| PCT/US1999/020900 WO2000029440A1 (fr) | 1998-11-12 | 1999-10-05 | Methodes de transformation d'isoformes d'interferons et produits ainsi obtenus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012327L NO20012327L (no) | 2001-05-11 |
| NO20012327D0 NO20012327D0 (no) | 2001-05-11 |
| NO329483B1 true NO329483B1 (no) | 2010-10-25 |
Family
ID=22701766
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012327A NO329483B1 (no) | 1998-11-12 | 2001-05-11 | Fremgangsmate for okning av utbyttet av et interferon alfa-preparat. |
| NO20100775A NO331699B1 (no) | 1998-11-12 | 2010-05-27 | Fremgangsmate for okning av utbyttet av et inerferon alfa-preparat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20100775A NO331699B1 (no) | 1998-11-12 | 2010-05-27 | Fremgangsmate for okning av utbyttet av et inerferon alfa-preparat |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP1129111B1 (fr) |
| JP (3) | JP4468585B2 (fr) |
| KR (1) | KR100922454B1 (fr) |
| CN (2) | CN100390197C (fr) |
| AR (1) | AR023906A1 (fr) |
| AT (2) | ATE476445T1 (fr) |
| AU (1) | AU766309B2 (fr) |
| BR (1) | BR9915257A (fr) |
| CA (1) | CA2348739C (fr) |
| CY (2) | CY1110444T1 (fr) |
| CZ (2) | CZ302402B6 (fr) |
| DE (2) | DE69942655D1 (fr) |
| DK (2) | DK1894944T3 (fr) |
| ES (2) | ES2348104T3 (fr) |
| HK (2) | HK1112746A1 (fr) |
| HU (1) | HU228265B1 (fr) |
| ID (1) | ID28552A (fr) |
| IL (2) | IL142546A0 (fr) |
| NO (2) | NO329483B1 (fr) |
| NZ (1) | NZ511074A (fr) |
| PL (2) | PL200274B1 (fr) |
| PT (2) | PT1129111E (fr) |
| SI (2) | SI1129111T1 (fr) |
| SK (2) | SK287564B6 (fr) |
| TW (1) | TW577894B (fr) |
| WO (1) | WO2000029440A1 (fr) |
| ZA (1) | ZA200103010B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1129111E (pt) * | 1998-11-12 | 2008-12-22 | Schering Corp | Métodos para a conversão de isoformas de interferão e seus produtos |
| JP2012513200A (ja) * | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | 組換え製造インターフェロンの精製 |
| CA3184298A1 (fr) * | 2020-04-20 | 2021-10-28 | Altum Pharmaceuticals Inc. | Interferon recombinant |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES498343A0 (es) | 1980-01-08 | 1983-09-01 | Biogen Nv | Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos. |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4315852A (en) | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
| US4364863A (en) | 1980-12-29 | 1982-12-21 | Schering Corporation | Extraction of interferon from bacteria |
| EP0082481B2 (fr) | 1981-12-23 | 1990-09-12 | Schering Corporation | Compositions stabilisées d'interféron alpha et leur préparation |
| DE3515336C2 (de) * | 1985-04-27 | 1994-01-20 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von â-Interferon |
| US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
| US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US4765903A (en) | 1987-10-06 | 1988-08-23 | Interferon Sciences, Inc. | Purification of monomeric interferon |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| AU648214B2 (en) * | 1991-12-31 | 1994-04-14 | Lucky Limited | Recombinant gene coding for human alpha interferon and expression vector thereof, etc. |
| ES2161793T3 (es) * | 1994-04-09 | 2001-12-16 | Hoffmann La Roche | Proceso para la produccion de alfa-interferona. |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| PT1129111E (pt) * | 1998-11-12 | 2008-12-22 | Schering Corp | Métodos para a conversão de isoformas de interferão e seus produtos |
-
1999
- 1999-10-05 PT PT99951431T patent/PT1129111E/pt unknown
- 1999-10-05 SK SK5003-2010A patent/SK287564B6/sk not_active IP Right Cessation
- 1999-10-05 ES ES07122953T patent/ES2348104T3/es not_active Expired - Lifetime
- 1999-10-05 NZ NZ511074A patent/NZ511074A/en not_active IP Right Cessation
- 1999-10-05 DE DE69942655T patent/DE69942655D1/de not_active Expired - Lifetime
- 1999-10-05 SI SI9931022T patent/SI1129111T1/sl unknown
- 1999-10-05 AT AT07122953T patent/ATE476445T1/de active
- 1999-10-05 IL IL14254699A patent/IL142546A0/xx unknown
- 1999-10-05 DK DK07122953.8T patent/DK1894944T3/da active
- 1999-10-05 BR BR9915257-6A patent/BR9915257A/pt not_active Application Discontinuation
- 1999-10-05 JP JP2000582425A patent/JP4468585B2/ja not_active Expired - Fee Related
- 1999-10-05 PL PL348162A patent/PL200274B1/pl not_active IP Right Cessation
- 1999-10-05 ID IDW00200101043A patent/ID28552A/id unknown
- 1999-10-05 AU AU63870/99A patent/AU766309B2/en not_active Ceased
- 1999-10-05 ES ES99951431T patent/ES2315019T3/es not_active Expired - Lifetime
- 1999-10-05 CN CNB998132136A patent/CN100390197C/zh not_active Expired - Fee Related
- 1999-10-05 HU HU0104113A patent/HU228265B1/hu unknown
- 1999-10-05 PL PL385501A patent/PL201341B1/pl not_active IP Right Cessation
- 1999-10-05 CZ CZ20011303A patent/CZ302402B6/cs not_active IP Right Cessation
- 1999-10-05 DE DE69939657T patent/DE69939657D1/de not_active Expired - Lifetime
- 1999-10-05 SI SI9931048T patent/SI1894944T1/sl unknown
- 1999-10-05 CN CNA2008100866846A patent/CN101255188A/zh active Pending
- 1999-10-05 EP EP99951431A patent/EP1129111B1/fr not_active Expired - Lifetime
- 1999-10-05 DK DK99951431T patent/DK1129111T3/da active
- 1999-10-05 AR ARP990105037A patent/AR023906A1/es active IP Right Grant
- 1999-10-05 CA CA2348739A patent/CA2348739C/fr not_active Expired - Fee Related
- 1999-10-05 TW TW088117149A patent/TW577894B/zh not_active IP Right Cessation
- 1999-10-05 EP EP07122953A patent/EP1894944B1/fr not_active Expired - Lifetime
- 1999-10-05 CZ CZ20110011A patent/CZ303110B6/cs not_active IP Right Cessation
- 1999-10-05 SK SK617-2001A patent/SK287372B6/sk not_active IP Right Cessation
- 1999-10-05 KR KR1020017005227A patent/KR100922454B1/ko not_active IP Right Cessation
- 1999-10-05 AT AT99951431T patent/ATE409706T1/de active
- 1999-10-05 PT PT07122953T patent/PT1894944E/pt unknown
- 1999-10-05 WO PCT/US1999/020900 patent/WO2000029440A1/fr active Application Filing
-
2001
- 2001-04-11 ZA ZA200103010A patent/ZA200103010B/en unknown
- 2001-04-11 IL IL142546A patent/IL142546A/en not_active IP Right Cessation
- 2001-05-11 NO NO20012327A patent/NO329483B1/no not_active IP Right Cessation
- 2001-09-06 HK HK08107904.2A patent/HK1112746A1/xx not_active IP Right Cessation
- 2001-09-06 HK HK01106287.8A patent/HK1035544A1/xx not_active IP Right Cessation
-
2006
- 2006-10-03 JP JP2006272306A patent/JP2006348056A/ja not_active Withdrawn
-
2008
- 2008-12-16 CY CY20081101455T patent/CY1110444T1/el unknown
-
2010
- 2010-05-27 NO NO20100775A patent/NO331699B1/no not_active IP Right Cessation
- 2010-06-17 JP JP2010138760A patent/JP2010209117A/ja not_active Withdrawn
- 2010-09-16 CY CY20101100841T patent/CY1110794T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6281337B1 (en) | Methods for conversion of protein isoforms | |
| Pote et al. | Otoconin-22, the major protein of aragonitic frog otoconia, is a homolog of phospholipase A2 | |
| US4771036A (en) | Method and ophthalmic composition for the prevention and reversal of cataracts | |
| BRPI0709737A2 (pt) | processo para concentraÇço de um polipeptÍdeo | |
| DE69710747T2 (de) | Assays für homocystein und homocysteindesulfurase aus protozoen trichomonas vaginalis | |
| NO331699B1 (no) | Fremgangsmate for okning av utbyttet av et inerferon alfa-preparat | |
| Pascale et al. | Biosynthesis and oligosaccharide structure of human CD8 glycoprotein expressed in a rat epithelial cell line. | |
| Kimura et al. | The primary structures of ribosomal proteins S14 and S16 from the archaebacterium Halobacterium marismortui. Comparison with eubacterial and eukaryotic ribosomal proteins. | |
| US6545140B1 (en) | DNA encoding an avian beta-defensin and uses thereof | |
| US6432671B1 (en) | Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition | |
| Kalisz et al. | Crystallization and preliminary X-ray analysis of tryparedoxin I from Crithidia fasciculata | |
| JP2003245094A (ja) | 無細胞系タンパク質合成方法およびそのための抽出液 | |
| JP4643932B2 (ja) | アメロゲニン融合タンパク質 | |
| EP0578472A2 (fr) | Procédé pour la récupération de peptides exprimées commes protéines fusionnées | |
| EP0620278A1 (fr) | Transaldolase humaine et DNA codant pour celle-ci | |
| JP2000116384A (ja) | 新規遺伝子及びそれにコ―ドされる蛋白質ｐｇｔｈ | |
| JPH09157298A (ja) | プロテアーゼインヒビター | |
| JPH09157299A (ja) | プロテアーゼインヒビター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US |
|
| MM1K | Lapsed by not paying the annual fees |